시장보고서

상품코드

1679569

점안제 시장 규모, 점유율, 동향 분석 보고서(2025-2030년) : 유형별, 약제 유형별, 치료 유형별, 지역별, 부문별 예측

Ophthalmic Eye Dropper Market Size, Share & Trends Analysis Report By Type (Unidose, Preserved, Preservative-free), By Drug Type (Prescription Drugs, OTC Drugs), By Treatment Type (Glaucoma, Allergies), By Region, And Segment Forecasts, 2025 - 2030

발행일: 2025년 02월 | 리서치사:

Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

점안제 시장의 성장과 동향

점안제 세계 시장 규모는 2030년에는 200억 2,000만 달러에 달할 것으로 예측되며, 2025-2030년에 걸쳐 CAGR 6.1%를 나타낼 것으로 예측됩니다. 녹내장, 노화 황반 변성, 안구 증후군 등 안 질환의 유병률이 세계적으로 상승하면서 점안제를 사용한 효율적인 치료에 대한 수요가 급증하고 있습니다. 게다가, 약물 전달 기술의 진보와 무보존 점안제의 도입은 치료 요법에 대한 환자의 순응도를 현저하게 향상시킵니다. 예를 들어, 무보존 점안제는 안전성이 높고 안구건조증 환자에게 선호되기 때문에 사용도가 높아질 것으로 생각됩니다.

백내장, 녹내장, 안구건조증 증후군, 알레르기 등의 안 질환 증가는 점안제 수요를 현저하게 높이고 있습니다. 예를 들어, National Glaucoma Research의 보고서에 따르면, 300만 명 이상의 미국인이 녹내장을 앓고 있으며, 그 중 270만 명은 40세 이상의 인구에서 유행하는 개방각 녹내장입니다. 이러한 유병률의 급증은 세계 인구의 고령화와 일치하며, 이러한 질병의 발생을 증가시키는 원인이 되었습니다. 그 결과, 점안제과 같은 효과적인 치료가 시급해지고 있습니다.

최적의 눈 건강 유지와 정기적인 안과 검진에 대한 의식이 높아지면서 점안제 수요가 향상되고 있습니다. 이러한 적극적인 접근법은 안과 문제를 더 빨리 치료하는 데 도움이 되며 안과 의료 제공업체와 점안제 제조 회사를 지원할 수 있습니다. 예를 들어, Alcon과 Bausch Lomb과 같은 기업은 다양한 눈 문제를 위해 특별한 점안제을 개발하여 시장 성장을 가속하고 있습니다.

점안제 시장 보고서 하이라이트

시장 성장 단계는 중간 정도이며, 그 속도는 기술, 제형, 점안제 전달 시스템의 발전 등 여러 요인에 의해 가속화되고 있습니다.
2024년에는 다회용 보존 점안제 부문이 48.5%의 최대 수익 점유율을 차지했습니다.
처방약 부문은 2024년에 61.3%의 최대 수익 점유율을 차지하였고 2025-2030년에 걸쳐 가장 높은 CAGR을 달성할 전망입니다.
안구건조증 부문은 2024년에 가장 큰 시장 점유율을 차지했습니다. 이는 디지털 장비의 장시간 사용, 환경 요인 및 노화로 인해 스포이드를 사용한 특정 치료가 필요하기 때문입니다.
북미 점안제 시장은 2024년 44.75%로 세계 시장을 독점했습니다.

정의와 범위
- 일회용 점안제
- 다회용 보존 점안제
- 다회용 무보존 점안제
유형별 시장 점유율(2024년 및 2030년)
부문 대시보드
유형별 점안제 세계 시장 전망
2018-2030년 시장 규모와 예측 및 동향 분석
- 일회용 점안제
- 다회용 보존 점안제
- 다회용 무보존 점안제

제5장 점안제 시장 : 약제 유형별, 추정 및 동향 분석

정의와 범위
- 처방약
- 시판약
약제 유형별 시장 점유율(2024년 및 2030년)
부문 대시보드
약제 유형별 점안제 세계 시장 전망
2018-2030년 시장 규모와 예측 및 동향 분석
- 처방약
- 시판약

제6장 점안제 시장 : 치료 유형별, 추정 및 동향 분석

정의와 범위
- 안구건조증
- 녹내장
- 알레르기
- 결막염
- 기타
치료 유형별 시장 점유율(2024년 및 2030년)
부문 대시보드
치료 유형별 점안제 세계 시장 전망
2018-2030년 시장 규모와 예측 및 동향 분석
- 안구건조증
- 녹내장
- 알레르기
- 결막염
- 기타

제7장 점안제 시장 : 지역별, 추정 및 동향 분석

지역별 시장 점유율 분석(2024년 및 2030년)
지역별 시장 대시보드
세계 지역 시장 현황
시장 규모와 예측 동향 분석(2018-2030년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진출기업에 의한 최근 동향과 영향 분석
기업/경쟁의 분류
- 혁신 기업
벤더 상황
- 주요 리셀러와 채널 파트너 목록
- 주요 기업의 시장 점유율 분석(2024년)
- AptarGroup, Inc
- Silgan Dispensing Systems
- Alcon plc
- Pfizer
- Bausch & Lomb Incorporated
- Novartis AG
- AbbVie Inc
- Santen Pharmaceutical Co., Ltd.
- Johnson & Johnson Vision
- Similasan Corporation

CSM 25.04.17

Ophthalmic Eye Dropper Market Growth & Trends:

The global ophthalmic eye dropper market size is anticipated to reach USD 20.02 billion in 2030 and is anticipated to grow at a CAGR of 6.1% from 2025 to 2030. The rising prevalence of eye disorders such as glaucoma, age-related macular degeneration, and eye syndrome among the aging population worldwide has surged the demand for efficient treatments delivered through eye droppers. Moreover, advancements in drug delivery technologies and the introduction of preservative-free eye drops have notably improved patient adherence to treatment regimens. For instance, preservative-free drops are considered safer and preferred by individuals with dry eyes, thus allowing more frequent use.

The rise in eye conditions such as cataracts, glaucoma, dry eye syndrome, and allergies has significantly bolstered the demand for ophthalmic eye drops. For instance, as reported by the National Glaucoma Research, over 3 million Americans live with glaucoma, out of which 2.7 million are affected by the prevalent open-angle glaucoma among those aged 40 and older. This surge in prevalence aligns with the aging global population, contributing to the increasing occurrence of these conditions. Consequently, there's a pressing necessity for effective treatments like eye drops to address these escalating eye health challenges.

The increased awareness about maintaining optimal eye health and regular eye check-ups has improved the demand for ophthalmic eye drops. This proactive approach helps treat ophthalmic issues quicker which allows eye care providers and eye drops manufacturing companies to assist. For instance, companies like Alcon and Bausch + Lomb have made special eye drops for different eye problems, thereby fueling the market growth.

Ophthalmic Eye Dropper Market Report Highlights:

The market growth stage is medium, and the pace is identified as accelerating owing to several factors, such as advancements in technology, formulations, and delivery systems for ophthalmic eye drops, which have significantly contributed to this growth.
The preserved multi-dose eye droppers segment accounted for the largest revenue share of 48.5% in 2024.
The prescription drugs segment accounted for the largest revenue share of 61.3% in 2024 and is expected to attain the fastest CAGR from 2025 to 2030.
The dry eye segment accounted for the largest market share in 2024, due to prolonged digital device use, environmental factors, and an aging population, which has heightened the need for specific treatments administered via eye droppers.
North America ophthalmic eye dropper market dominated the global market 44.75% in 2024.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Drug Type
- 1.1.3. Treatment
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
- 1.3.1. Purchased database.
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
  - 1.3.5.1. Data for Primary Interviews in North America
  - 1.3.5.2. Data for Primary Interviews in Europe
  - 1.3.5.3. Data for Primary Interviews in Asia Pacific
  - 1.3.5.4. Data for Primary Interviews in Latin America
  - 1.3.5.5. Data for Primary Interviews in MEA
1.4. Information or Data Analysis
- 1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
  - 1.6.1.1. Approach 1: Commodity flow approach
- 1.6.2. Volume price analysis (Model 2)
  - 1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Drug Type
- 2.2.3. Treatment Type
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Ophthalmic Eye Dropper Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Increasing prevalence of eye disorders
  - 3.2.1.2. Technological advancements in drug delivery systems
  - 3.2.1.3. Aging population and lifestyle changes
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Limited patient compliance
3.3. Ophthalmic Eye Dropper Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape

Chapter 4. Ophthalmic Eye Dropper Market: Type Estimates & Trend Analysis

4.1. Definitions and Scope
- 4.1.1. Unidose eye droppers
- 4.1.2. Preserved multi-dose eye droppers
- 4.1.3. Preservative-free multi-dose eye droppers
4.2. Type Market Share, 2024 & 2030
4.3. Segment Dashboard
4.4. Global Ophthalmic Eye Dropper Market by Type Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5.1. Unidose eye droppers
  - 4.5.1.1. Unidose eye Droppers Market Estimates and Forecast 2018 to 2030 (USD Million)
- 4.5.2. Preserved multi-dose eye droppers
  - 4.5.2.1. Preserved multi-dose eye droppers market estimates and forecast 2018 to 2030 (USD Million)
- 4.5.3. Preservative-free multi-dose eye droppers
  - 4.5.3.1. Preservative-free multi-dose eye Droppers Market Estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Ophthalmic Eye Dropper Market: Drug Type Estimates & Trend Analysis

5.1. Definitions and Scope
- 5.1.1. Prescription drugs
- 5.1.2. OTC drugs
5.2. Drug Type Market Share, 2024 & 2030
5.3. Segment Dashboard
5.4. Global Ophthalmic Eye Dropper Market by Drug Type Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5.1. Prescription drugs
  - 5.5.1.1. Prescription drugs market estimates and forecast 2018 to 2030 (USD Million)
- 5.5.2. OTC drugs
  - 5.5.2.1. OTC drugs market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Ophthalmic Eye Dropper Market: Treatment Type Estimates & Trend Analysis

6.1. Definitions and Scope
- 6.1.1. Dry Eye
- 6.1.2. Glaucoma
- 6.1.3. Allergies
- 6.1.4. Conjunctivitis
- 6.1.5. Others
6.2. Treatment Type Market Share, 2024 & 2030
6.3. Segment Dashboard
6.4. Global Ophthalmic Eye Dropper Market by Treatment Type Outlook
6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5.1. Dry Eye
  - 6.5.1.1. Dry eye market estimates and forecasts for 2018 to 2030 (USD Million)
- 6.5.2. Glaucoma
  - 6.5.2.1. Glaucoma market estimates and forecasts for 2018 to 2030 (USD Million)
- 6.5.3. Allergies
  - 6.5.3.1. Allergies market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.4. Conjunctivitis
  - 6.5.4.1. Conjunctivitis market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.5. Others
  - 6.5.5.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Ophthalmic Eye Dropper Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
- 7.5.1. U.S.
  - 7.5.1.1. Key country dynamics
  - 7.5.1.2. Competitive scenario
  - 7.5.1.3. Regulatory framework
  - 7.5.1.4. Reimbursement scenario
  - 7.5.1.5. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.2. Canada
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Competitive scenario
  - 7.5.2.3. Regulatory framework
  - 7.5.2.4. Reimbursement scenario
  - 7.5.2.5. Canada market estimates and forecast, 2018 - 2030 (USD Million)
- 7.5.3. Mexico
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Competitive scenario
  - 7.5.3.3. Regulatory framework
  - 7.5.3.4. Reimbursement scenario
  - 7.5.3.5. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
7.6. Europe
- 7.6.1. UK
  - 7.6.1.1. Key country dynamics
  - 7.6.1.2. Competitive scenario
  - 7.6.1.3. Regulatory framework
  - 7.6.1.4. Reimbursement scenario
  - 7.6.1.5. UK market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.2. Germany
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Competitive scenario
  - 7.6.2.3. Regulatory framework
  - 7.6.2.4. Reimbursement scenario
  - 7.6.2.5. Germany market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.3. France
  - 7.6.3.1. Key country dynamics
  - 7.6.3.2. Competitive scenario
  - 7.6.3.3. Regulatory framework
  - 7.6.3.4. Reimbursement scenario
  - 7.6.3.5. France market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.4. Italy
  - 7.6.4.1. Key country dynamics
  - 7.6.4.2. Competitive scenario
  - 7.6.4.3. Regulatory framework
  - 7.6.4.4. Reimbursement scenario
  - 7.6.4.5. Italy market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.5. Spain
  - 7.6.5.1. Key country dynamics
  - 7.6.5.2. Competitive scenario
  - 7.6.5.3. Regulatory framework
  - 7.6.5.4. Reimbursement scenario
  - 7.6.5.5. Spain market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.6. Norway
  - 7.6.6.1. Key country dynamics
  - 7.6.6.2. Competitive scenario
  - 7.6.6.3. Regulatory framework
  - 7.6.6.4. Reimbursement scenario
  - 7.6.6.5. Norway market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.7. Sweden
  - 7.6.7.1. Key country dynamics
  - 7.6.7.2. Competitive scenario
  - 7.6.7.3. Regulatory framework
  - 7.6.7.4. Reimbursement scenario
  - 7.6.7.5. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
- 7.6.8. Denmark
  - 7.6.8.1. Key country dynamics
  - 7.6.8.2. Competitive scenario
  - 7.6.8.3. Regulatory framework
  - 7.6.8.4. Reimbursement scenario
  - 7.6.8.5. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
7.7. Asia Pacific
- 7.7.1. Japan
  - 7.7.1.1. Key country dynamics
  - 7.7.1.2. Competitive scenario
  - 7.7.1.3. Regulatory framework
  - 7.7.1.4. Reimbursement scenario
  - 7.7.1.5. Japan market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.2. China
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Competitive scenario
  - 7.7.2.3. Regulatory framework
  - 7.7.2.4. Reimbursement scenario
  - 7.7.2.5. China market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.3. India
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Competitive scenario
  - 7.7.3.3. Regulatory framework
  - 7.7.3.4. Reimbursement scenario
  - 7.7.3.5. India market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.4. Australia
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Competitive scenario
  - 7.7.4.3. Regulatory framework
  - 7.7.4.4. Reimbursement scenario
  - 7.7.4.5. Australia market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.5. South Korea
  - 7.7.5.1. Key country dynamics
  - 7.7.5.2. Competitive scenario
  - 7.7.5.3. Regulatory framework
  - 7.7.5.4. Reimbursement scenario
  - 7.7.5.5. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
- 7.7.6. Thailand
  - 7.7.6.1. Key country dynamics
  - 7.7.6.2. Competitive scenario
  - 7.7.6.3. Regulatory framework
  - 7.7.6.4. Reimbursement scenario
  - 7.7.6.5. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
7.8. Latin America
- 7.8.1. Brazil
  - 7.8.1.1. Key country dynamics
  - 7.8.1.2. Competitive scenario
  - 7.8.1.3. Regulatory framework
  - 7.8.1.4. Reimbursement scenario
  - 7.8.1.5. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
- 7.8.2. Argentina
  - 7.8.2.1. Key country dynamics
  - 7.8.2.2. Competitive scenario
  - 7.8.2.3. Regulatory framework
  - 7.8.2.4. Reimbursement scenario
  - 7.8.2.5. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
7.9. MEA
- 7.9.1. South Africa
  - 7.9.1.1. Key country dynamics
  - 7.9.1.2. Competitive scenario
  - 7.9.1.3. Regulatory framework
  - 7.9.1.4. Reimbursement scenario
  - 7.9.1.5. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
- 7.9.2. Saudi Arabia
  - 7.9.2.1. Key country dynamics
  - 7.9.2.2. Competitive scenario
  - 7.9.2.3. Regulatory framework
  - 7.9.2.4. Reimbursement scenario
  - 7.9.2.5. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
- 7.9.3. UAE
  - 7.9.3.1. Key country dynamics
  - 7.9.3.2. Competitive scenario
  - 7.9.3.3. Regulatory framework
  - 7.9.3.4. Reimbursement scenario
  - 7.9.3.5. UAE market estimates and forecast, 2018 - 2030 (USD Million)
- 7.9.4. Kuwait
  - 7.9.4.1. Key country dynamics
  - 7.9.4.2. Competitive scenario
  - 7.9.4.3. Regulatory framework
  - 7.9.4.4. Reimbursement scenario
  - 7.9.4.5. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
- 8.2.1. Innovators
8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2024
- 8.3.4. AptarGroup, Inc
  - 8.3.4.1. Company overview
  - 8.3.4.2. Financial performance
  - 8.3.4.3. Product benchmarking
  - 8.3.4.4. Strategic initiatives
- 8.3.5. Silgan Dispensing Systems
  - 8.3.5.1. Company overview
  - 8.3.5.2. Financial performance
  - 8.3.5.3. Product benchmarking
  - 8.3.5.4. Strategic initiatives
- 8.3.6. Alcon plc
  - 8.3.6.1. Company overview
  - 8.3.6.2. Financial performance
  - 8.3.6.3. Product benchmarking
  - 8.3.6.4. Strategic initiatives
- 8.3.7. Pfizer
  - 8.3.7.1. Company overview
  - 8.3.7.2. Financial performance
  - 8.3.7.3. Product benchmarking
  - 8.3.7.4. Strategic initiatives
- 8.3.8. Bausch & Lomb Incorporated
  - 8.3.8.1. Company overview
  - 8.3.8.2. Financial performance
  - 8.3.8.3. Product benchmarking
  - 8.3.8.4. Strategic initiatives
- 8.3.9. Novartis AG
  - 8.3.9.1. Company overview
  - 8.3.9.2. Financial performance
  - 8.3.9.3. Product benchmarking
  - 8.3.9.4. Strategic initiatives
- 8.3.10. AbbVie Inc
  - 8.3.10.1. Company overview
  - 8.3.10.2. Financial performance
  - 8.3.10.3. Product benchmarking
  - 8.3.10.4. Strategic initiatives
- 8.3.11. Santen Pharmaceutical Co., Ltd.
  - 8.3.11.1. Company overview
  - 8.3.11.2. Financial performance
  - 8.3.11.3. Product benchmarking
  - 8.3.11.4. Strategic initiatives
- 8.3.12. Johnson & Johnson Vision
  - 8.3.12.1. Company overview
  - 8.3.12.2. Financial performance
  - 8.3.12.3. Product benchmarking
  - 8.3.12.4. Strategic initiatives
- 8.3.13. Similasan Corporation
  - 8.3.13.1. Company overview
  - 8.3.13.2. Financial performance
  - 8.3.13.3. Product benchmarking
  - 8.3.13.4. Strategic initiatives